Lv11
20 积分 2024-11-21 加入
[Clinical practice guidelines for adult patients with IgA nephropathy and IgA vasculitis-associated nephritis in China (2025)]
8小时前
待确认
Biomarker profiles in idiopathic and progressive pulmonary fibrosis after LPA1 antagonism: exploratory analysis from a phase 2 trial of admilparant
19天前
已完结
Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial
1个月前
已完结
Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy
1个月前
已完结
Lysophosphatidic acid promotes colitis-associated intestinal fibrosis by suppressing autophagy via LPAR3/ AMPK/mTOR pathway
2个月前
已完结
Necessity of Lysophosphatidic Acid Receptor 1 for Development of Arthritis
2个月前
已完结
Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis
2个月前
已完结
LPA1 Receptor Activation Promotes Renal Interstitial Fibrosis
2个月前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
2个月前
已完结
Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial
2个月前
已完结
皖公网安备34019202002308
